Verrica Pharmaceuticals Inc.·3

Jan 26, 4:23 PM ET

BKB Growth Investments, LLC 3

3 · Verrica Pharmaceuticals Inc. · Filed Jan 26, 2026

Insider Transaction Report

Form 3
Period: 2025-11-25
Holdings
  • Common Stock

    3,348,372
  • Series B Warrants (right to buy)

    [F1][F2]
    Exercise: $1.33Exp: 2029-11-22Common Stock (224,719 underlying)
  • Series C Warrants (right to buy)

    [F1][F3]
    Exercise: $6.32Exp: 2030-11-25Common Stock (687,690 underlying)
Footnotes (3)
  • [F1]Immediately exercisable.
  • [F2]The Reporting Person will not be entitled to exercise any portion of a Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 19.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
  • [F3]The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 19.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
Signature
BKB Growth Investments, LLC, By: Tiger Lily Capital, LLC, its manager By: /s/ Paul Manning, its manager|2026-01-26

Documents

1 file
  • 3
    form3-01262026_090154.xmlPrimary